Tags : ANNOUNCE

Eli Lilly Reports Results of Lartruvo (olaratumab) in ANNOUNCE P-III

Shots: The P-III ANNOUNCE study involves assessing of Lartruvo + doxorubicin following lartruvo monothx vs doxorubicin + PBO following PBO monothx in patients with advanced or metastatic STS The study didn’t meet 1EP as OS showing no difference in survival rate with no safety signals observed; AEs (all grades; grade 3-4) fatigue (69%,9% vs 3% […]Read More